** Shares of drugmaker Perrigo PRGO.N up 6.78% at $27
** Co reports Q1 adj. profit of $0.60 per share, above analysts' estimate of $0.55 per share, according to data compiled by LSEG
** Also reaffirms all previously provided 2025 financial targets, including adj. EPS range
** Widens 2025 net sales growth target range to 0%-3%, due to macroeconomic uncertainty, vs analysts' estimate of 1.42% growth
** "Maintaining margins and profit guidance is positive, showing management's good visibility into execution benefits. '25 is largely a self-help year" - Jefferies
** Co posts Q1 net sales of $1.04 billion
** As of last close, stock was up ~1.91% YTD
(Reporting by Megha Kumari)
((Megha.Kumari@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。